Kioxia Announces English Version of World’s First AI-Designed Manga
3.6.2020 12:30:00 EEST | Business Wire | Press release
Kioxia Corporation today announced that an English version of “PHAEDO,” a new manga created and designed by AI and human collaboration, inspired by the artistic style of manga legend Osamu Tezuka, will be released on June 3 as part of TEZUKA 2020, the first phase of Kioxia’s #FutureMemories brand campaign. PHAEDO, which debuted in February in Japanese comic magazine “Morning,” will be made available for English-language audiences on Kioxia’s TEZUKA 2020 website. PHAEDO is the world’s first1 international manga created through human collaboration, high-speed and large-capacity memory and advanced AI technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200603005356/en/
"PHAEDO" (Graphic: Business Wire)
The process of developing PHAEDO involved using AI technology to generate the story and create the characters. As a first step, to learn the essence of Tezuka’s work and his characteristics as a writer, AI analyzed 130 manga episodes, written and drawn by Osamu Tezuka, including globally famous titles such as “Astro Boy” and “Black Jack”. Based on this analysis, the AI then generated 129 candidate storylines. As a next step, the AI studied 6000 images and applied transfer learning to generate visuals for the characters.
By analyzing Tezuka’s works, AI was able to generate the physical characteristics of new characters, outlines of new stories, after which illustrators hand-drew clothing and other Tezuka inspired details and writers added dialogue. The project team consisted of engineers from Kioxia, who optimize semiconductor fab productivity and product performance using AI technology, illustrators and writers from Tezuka Productions Co., and AI researchers from Keio University and Future University Hakodate.
PHAEDO is the story of a homeless philosopher and his robot bird, Apollo, who try to solve crimes in Tokyo in 2030. This marks the first time Tezuka’s work has been recreated in 30 years.
Kioxia launched its #FutureMemories campaign last October to commemorate the company’s rebranding as Kioxia. PHAEDO is one of the many ways Kioxia intends to change the world by pursuing the potential of memory to create new value with never-before-seen experiences.
For details about PHAEDO, including videos and interviews, please visit TEZUKA 2020 website.
Notes
1. As of June 3, 2020. Kioxia Corporation research.
About Kioxia
Kioxia is a world leader in memory solutions, dedicated to the development, production and sale of flash memory and solid state drives (SSDs). In April 2017, its predecessor Toshiba Memory was spun off from Toshiba Corporation, the company that invented NAND flash memory in 1987. The company pioneers cutting-edge memory solutions and services that enrich people's lives and expand society's horizons. Kioxia's innovative 3D flash memory technology, BiCS FLASH™, is shaping the future of storage in high-density applications, including advanced smartphones, PCs, SSDs, automotive and data centers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200603005356/en/
Contact information
For more information
Sam Ghirardello (phone: +81-3-5427-7396, SGhirardello@webershandwick.com)
Satoshi Ito (phone: +81-3-5427-7309, SIto@webershandwick.com)
Weber Shandwick (Tokyo)
Natalie Telson (ntelson@webershandwick.com)
Weber Shandwick (New York)
Public Relations
Kota Yamaji (kioxia-hd-pr@kioxia.com
)
Kioxia Holdings Corporation
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom